ESH MDS 2024 | Immune checkpoint inhibitors in MDS: the i4MDS consortium

Shahram Kordasti, MSc, MD, PhD, King’s College London, London, UK, shares his thoughts on the potential therapeutic capacity of immune checkpoint inhibitors (ICIs) in patients with myelodysplastic syndromes (MDS). Although results have not been particularly encouraging, they are not a definitive indicator for the future use of ICIs in MDS, as a small proportion of patients do respond to these agents. Patient immune system fitness may be a significant predictive factor for treatment responsiveness, meaning that optimization of treatment timing is likely needed to improve clinical outcomes. Dr Kordasti shares insights into a consortium being formed, supported by the European Haematology Association (EHA), which aims to standardize immune profiling in MDS. The International Integrative Innovative Immunology for MDS (i4MDS) holds immense potential for improving patient stratification and outcomes. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.